Daily Stock Analysis, BGNE, BeiGene Ltd, priceseries

BeiGene Ltd. Daily Stock Analysis
Stock Information
Open
85.65
Close
85.26
High
85.65
Low
81.77
Previous Close
85.14
Daily Price Gain
0.12
YTD High
87.77
YTD High Date
Sep 20, 2017
YTD Low
29.58
YTD Low Date
Jan 3, 2017
YTD Price Change
54.21
YTD Gain
174.59%
52 Week High
87.77
52 Week High Date
Sep 20, 2017
52 Week Low
26.43
52 Week Low Date
Dec 8, 2016
52 Week Price Change
55.76
52 Week Gain
189.02%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 31. 2016
28.25
Jun 9. 2016
30.05
7 Trading Days
6.37%
Link
LONG
Jan 23. 2017
32.39
Feb 7. 2017
34.41
11 Trading Days
6.22%
Link
LONG
Feb 10. 2017
36.00
Feb 23. 2017
37.84
8 Trading Days
5.11%
Link
LONG
Apr 24. 2017
37.61
May 4. 2017
39.82
8 Trading Days
5.88%
Link
LONG
Jun 16. 2017
41.56
Jul 24. 2017
72.26
25 Trading Days
73.86%
Link
Company Information
Stock Symbol
BGNE
Exchange
NasdaqGS
Company URL
http://http://www.beigene.com
Company Phone
13459494123
CEO
John V. Oyler
Headquarters
-
Business Address
C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, CAYMAN ISLANDS KY1-1108
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001651308
About

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, the Cayman Islands.